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A B S T R A C T   
Cortical injury, such as stroke, causes neurotoxic cascades that lead to rapid death and/or damage to neurons and 
glia. Axonal and myelin damage in particular, are critical factors that lead to neuronal dysfunction and impair 
recovery of function after injury. These factors can be exacerbated in the aged brain where white matter damage 
is prevalent. Therapies that can ameliorate myelin damage and promote repair by targeting oligodendroglia, the 
cells that produce and maintain myelin, may facilitate recovery after injury, especially in the aged brain where 
these processes are already compromised. We previously reported that a novel therapeutic, Mesenchymal Stem 
Cell derived extracellular vesicles (MSC-EVs), administered intravenously at both 24 h and 14 days after cortical 
injury, reduced microgliosis (Go et al. 2019), reduced neuronal pathology (Medalla et al. 2020), and improved 
motor recovery (Moore et al. 2019) in aged female rhesus monkeys. Here, we evaluated the effect of MSC-EV 
treatment on changes in oligodendrocyte maturation and associated myelin markers in the sublesional white 
matter using immunohistochemistry, confocal microscopy, stereology, qRT-PCR, and ELISA. Compared to vehicle 
control monkeys, EV-treated monkeys showed a reduction in the density of damaged oligodendrocytes. Further, 
EV-treatment was associated with enhanced myelin maintenance, evidenced by upregulation of myelin-related 
genes and increases in actively myelinating oligodendrocytes in sublesional white matter. These changes in 
myelination correlate with the rate of motor recovery, suggesting that improved myelin maintenance facilitates 
this recovery. Overall, our results suggest that EVs act on oligodendrocytes to support myelination and improves 
functional recovery after injury in the aged brain. 
Significance: We previously reported that EVs facilitate recovery of function after cortical injury in the aged 
monkey brain, while also reducing neuronal pathology (Medalla et al. 2020) and microgliosis (Go et al. 2019). 
However, the effect of injury and EVs on oligodendrocytes and myelination has not been characterized in the 
primate brain (Dewar et al. 1999; Sozmen et al. 2012; Zhang et al. 2013). In the present study, we assessed 
changes in myelination after cortical injury in aged monkeys. Our results show, for the first time, that MSC-EVs 
support recovery of function after cortical injury by enhancing myelin maintenance in the aged primate brain.  
Abbreviations: EVs, extracellular vesicles; MSC, Mesenchymal Stem Cells; SW, sublesional white matter; OPCs, oligodendrocyte precursor cells; MBP, Myelin Basic 
Protein. 
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1. Introduction 
Cortical injury, such as stroke or age-related pathology, causes rapid 
apoptosis and necrosis of neurons and glia. Damage to axons and myelin, 
in particular, are crucial factors that contribute to neuronal dysfunction 
and is often exacerbated in the aged brain where white matter damage is 
prevalent. Oligodendrocytes, cells that produce and maintain myelin, 
facilitate neuronal function in the Central Nervous System (CNS). Spe-
cifically, oligodendrocytes support neurons by providing axonal stabil-
ity, maintaining axonal metabolism, and improving axonal conduction. 
While oligodendrocytes are critical for normal neuronal function, they 
are extremely susceptible to cytotoxic and inflammatory damage asso-
ciated with neurotraumatic injuries - especially in the aged brain - due to 
the release of cytotoxic proteases, inflammatory cytokines, and reactive 
oxygen species (Arai and Lo 2009; Chavez et al. 2009; Lakhan et al. 
2009; Wang et al. 2016). These cytotoxic agents produce lasting damage 
to oligodendrocytes, in addition to neurons and other glial cells, thus 
causing injury to cells necessary to support neurological functions 
(Wang et al. 2007; Arai and Lo 2009). With such impairments in oli-
godendrocytes, neurons become increasingly susceptible to structural 
and functional disturbances (Wang et al. 2007; Chavez et al. 2009)and, 
resulting in sustained neuronal dysfunction (Duncan et al. 1997; Wang 
et al. 2016). 
Myelin pathology and oligodendrocyte dysfunction are prevalent in 
the aged brain and likely contribute to age-related susceptibility to brain 
injury and subsequent neuronal dysfunction (Bowley et al. 2010; Shobin 
et al. 2017). In particular, oligodendrocytes found in the aged brain are 
more susceptible to increased levels of degrading enzymes such as cal-
pain (Sloane et al. 2003) as well as increased levels of oxidative damage 
to oligodendroglial DNA (Tse and Herrup 2017). Additionally, oligo-
dendroglia have reduced proliferative and differentiation capabilities 
with increased age, thus dampening their ability to restore myelin 
(Miyamoto et al. 2013; El Waly et al. 2014; Rivera et al. 2016). In 
essence, increased susceptibility to damage and degradation of oligo-
dendrocytes, as well as reduced oligodendrogenesis associated with age, 
results in decreased myelination and oligodendrocyte function which 
can contribute to reduced neurological function. Hence, limiting the 
extent of oligodendrocyte damage and facilitating oligodendrocyte 
proliferation and maturation could enhance myelin maintenance and 
promote neurorestoration in aged, injured, and diseased brains (Arai 
and Lo 2009; Takase et al. 2018). Therefore, therapeutic agents that 
facilitate myelin maintenance may improve neurological outcomes 
following injury, especially in the aged brain. 
One promising novel therapy is extracellular vesicles (EVs) derived 
from bone marrow Mesenchymal Stem Cells (MSCs), which have been 
shown to produce regenerative effects for brain injury and neuro-
degeneration via restorative processes such as immunomodulation, 
angiogenesis, neurogenesis, and synaptogenesis both in vivo and in vitro 
in rodent, porcine, and primate models (Chopp and Li 2002; Zhang et al. 
2019; Moore et al., 2019). While cell-based therapies, including MSCs, 
have been useful for restorative therapy, the mechanism is likely 
through the release of EVs, which are nano-scale vesicles that contain 
miRNA, mRNA, and protein that are crucial for intercellular communi-
cation (Xin et al. 2012). These EVs are taken up by a recipient cell, which 
putatively responds to the molecular content delivered by the EVs. 
Currently, the effects of EV therapy on oligodendrocytes and myelin in 
vivo are largely unknown, especially in the aged primate brain. 
Our previous work has tested EVs as a therapeutic for brain injury in 
rodent and porcine models (Chopp and Li 2002; Zhang et al. 2019). Most 
recently, we tested the therapeutic potential of MSC-EVs for enhancing 
motor recovery following cortical injury in the hand representation of 
the primary motor cortex of aged monkeys (Moore et al. 2019). Aged 
monkeys treated with MSC-EVs recovered fine motor function of the 
hand and digits within 3–5 weeks compared to aged monkeys in the 
vehicle control group (PBS) which exhibited a more limited recovery 
(Moore et al. 2019). Further, we have shown that EV treatment reduces 
microgliosis (Go et al. 2019) and neuronal pathology (Medalla et al. 
2020) in the aged brain, which could partially explain the enhancement 
of motor recovery described in (Moore et al. 2019). However, the 
downstream effects of EVs on myelin remains unclear. In the present 
study, we used archived tissue from the same aged brains studied in 
Moore et al. (2019) and assessed myelination with and without EV 
treatment after cortical injury. To our knowledge, this is the first study 
to assess the effects of MSC-EVs on myelination after cortical injury in 
aged rhesus monkeys. 
2. Methods 
2.1. Subjects 
Brain tissue used in this study was from nine aged female rhesus 
monkeys used in Moore et al. 2019. The monkeys ranged in age from 16 
to 26 years old (analogous to humans approximately 48 to 78 years old, 
Tigges et al. 1988, Supplementary Table 1). Monkeys were acquired 
from national research primate centers and private vendors, and were 
maintained in the Animal Science Center of Boston University Medical 
Campus (fully AAALAC accredited). Experiments were approved by the 
Boston University Institutional Animal Care and Use Committee. During 
the study, aged monkeys were individually housed within visual and 
auditory range of other monkeys in the colony room. Enrichment pro-
cedures used either met or exceeded USDA requirements. Aged monkeys 
were fed once a day, immediately following testing, and water was 
available continuously. Diet consisted of a commercial monkey chow 
that was supplemented with fruits and vegetables. Before entering the 
study, monkeys were assessed for pre-existing abnormalities in overall 
health. As detailed in Moore et al. (2019), monkeys were trained on a 
fine motor task then randomly assigned to a vehicle control or EV 
treatment before receiving a cortical injury targeted to the hand repre-
sentation of the primary motor cortex (M1). Following injury, they were 
given intravenous vehicle control (PBS) or EV treatment (4 × 1011 
particles/kg) at 24 h after surgery and again at 14 days after surgery. All 
staff were blinded to the treatment groups for all procedures and 
experiments. 
2.2. Mesenchymal stem cell-derived extracellular vesicle preparation and 
administration 
EVs were isolated from bone marrow derived MSCs of a young 
monkey, as described previously (Xin et al. 2013; Moore et al. 2019). 
Briefly, a young monkey (approximately 5 years old - equivalent to 15 
human years) was sedated with ketamine (10 mg/kg IM), then anes-
thetized with sodium pentobarbital (15–25 mg/kg IV). Bone marrow 
was extracted from the iliac crest and shipped on wet ice, with same day 
delivery to Henry Ford Health Systems in Detroit. Upon arrival, marrow 
was spun at 4000 xg for 15 min to separate cells. The buffy coat was 
discarded, and remaining cells were washed in culture medium. Cells 
were then plated in a T75 flask using media containing 20% FBS and 
alpha-MEM, grown to confluence, and passaged as necessary. To grow 
enough cells for EVs, 10 × 106 cells were seeded into a Quantum 
Incubator (Terumo BCT, Lakewood, CO) and grown in alpha-MEM with 
10% EV-depleted FBS (Systems Biosciences, Palo Alto, CA). To harvest 
EVs, media was collected every other day for four days, then every day 
for two days. As described in Zhang et al. (2015), media was centrifuged 
in multiple stages at 250 xg for 5 min, then 3000 xg for 30 min, then 
filtered and centrifuged a final time at 100,000 xg for 2 h to pellet EVs. 
The pellet was resuspended in a small volume of PBS. EV concentrations 
and particle sizes were measured using a qNano (Izon, Cambridge, MA, 
United States), then diluted to 4 × 1011 particles/kg for each monkey in 
4 mL of PBS. EVs had an average diameter of 111 nm in size (Supple-
mentary Fig. 1), and had confirmed expression of CD9, CD81, and CD63 
by western blot, per MISEV guidelines (data not shown) (Witwer et al. 
2017). The dose was chosen based on previous dosing studies conducted 
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in rats (Xin et al. 2013; Zhang et al. 2015). Following resuspension, EVs 
were stored at 4 ◦C until the day before treatment, then shipped to 
Boston University the day prior to intravenous administration in 
monkeys. 
2.3. Motor testing and lesion of the M1 hand representation 
To assess motor function, monkeys were trained on the Hand Dex-
terity Task (HDT) for five weeks, a modified version of the Klüver board, 
as described in (Moore et al. 2012, 2013, 2019). After pre-training, the 
dominant hand was determined using free choice trials. To create an 
injury in the hand representation of M1, a craniotomy was performed 
over the contralateral hemisphere of the dominant hand. The dura was 
opened, and the precentral gyrus was electrophysiologically mapped 
using a small silver ball surface electrode to locate the precise area of M1 
that controlled hand and digit function. Using this map, a small incision 
was made in pia above the hand representation, and a small glass suction 
pipette was placed under the pia to bluntly separate penetrating arte-
rioles from the underlying cortex in the mapped area as well as through 
the adjacent anterior bank of the central sulcus. This approach disrupts 
the blood supply to the underlying cortex without mechanically 
damaging the underlying grey matter. After injury, monkeys were given 
two weeks to recover, then monkeys resumed fine motor testing for 12 
weeks to assess the rate and extent of recovery of fine motor function on 
the HDT, with and without EV treatment. 
2.4. Cerebrospinal fluid extraction 
Cerebrospinal fluid (CSF) was drawn at multiple time points across 
the recovery period (Baseline (Pre-surgery), 14 days after injury, 28 days 
after injury, 6 weeks after injury, and at euthanasia 14 weeks after 
injury) to assess Myelin Basic Protein. Briefly, monkeys were sedated 
with Ketamine (10 mg/kg IM), CSF was drawn from the cisterna magna 
and immediately placed in 4 ◦C for temporary storage (less than 2 h), 
then frozen and stored at − 80 ◦C until processed. 
2.5. Brain tissue section preparation and storage 
Following completion of motor testing (Moore et al. 2012, 2013, 
2019) monkeys were sedated with ketamine (10 mg/kg IM) and anes-
thetized with intravenous sodium pentobarbital (25 mg/kg IV to effect). 
While under a surgical level of anesthesia, the chest was opened and 
monkeys were euthanized by exsanguination during transcardial 
perfusion-fixation of the brain, first with cold Krebs-Heinsleit buffer 
(4 ◦C, pH 7.4) during which fresh tissue biopsies were collected, after 
which the perfusate was switched to 4% paraformaldehyde (30 ◦C, pH 
7.4) to fix the brain. Fresh tissue was immediately snap frozen in pul-
verized dry ice, then stored at − 80 ◦C until processed. 
The fixed brains were blocked, in situ, in the coronal plane, removed 
from the skull, and cryoprotected in a solution of 0.1 M phosphate 
buffer, 10% glycerol, and 2% DMSO followed by buffer with 2% DMSO 
and 20% glycerol. Brains were then flash frozen at − 75 ◦C in isopentane 
and stored at − 80 ◦C (Rosene et al., 1986). For histological analyses, 
brains were removed from the − 80 ◦C storage and cut on a microtome in 
the coronal plane into interrupted series (8 series of 30 μm sections, and 
one 60 μm section series) giving a 300 μm spacing between sections in 
each series. If not processed immediately, sections were transferred to 
cryoprotectant (15% glycerol in buffer) and stored at − 80 ◦C until 
thawed for immunohistochemistry. 
2.6. Regions of interest 
Sections containing the lesion were first identified in a series of 
thionin stained coronal sections from each monkey based on the pres-
ence of tissue damage in the hand area of primary motor cortex, indi-
cated by glial scarring, disrupted neuronal profiles, and discontinuity of 
the pial surface and cortical lamination, as described previously (Orc-
zykowski et al., 2018). Within the range of sections containing the 
lesion, a subset of sections spaced 2400 μm apart was selected for further 
analysis with defined the regions of interest (ROI) which included the 
sublesional white matter (SW) - delineated as the white matter imme-
diately beneath the grey matter lesion. Coronal sections from adjacent 
series were matched to thionin-stained sections containing the lesion 
and selected for immunofluorescent labeling of markers (Fig. 1A). To 
illustrate the typical distribution of oligodendrocytes in a normal, aged 
brain, images from the white matter from the contralateral primary 
motor cortex were scanned and denoted as “controls”, as shown in 
Figs. 2, 4, and 5. 
2.7. Fluorescent immunohistochemistry of oligodendroglial markers 
Three tissue sections through the lesion, spaced 2400 μm apart 
(selected based on the thionin series), were removed from − 80 ◦C, 
thawed, and batch processed with immunohistochemistry to assess 
oligodendroglial markers. Sections were washed with PBS, blocked 
using Superblock (ThermoFisher, Waltham, MA, USA), then incubated 
overnight at RT with primary antibodies (single, double, or triple- 
labeled) to rabbit anti-BCAS1 (marker of newly myelinating oligoden-
drocytes, Abcam, ab106661, Fard et al. 2017), mouse anti-CC1 (marker 
of mature oligodendrocytes, Abcam, ab16794), rabbit anti-Olig2 
(marker of all oligodendrocyte lineage, Abcam, ab42453), mouse anti- 
8OHdG (marker of oxidative DNA damage, Abcam, ab62623), and 
rabbit anti-NG2 (marker of Oligodendrocyte Precursor Cells, Abcam, 
ab129051) in a PBS solution containing 0.5% Superblock and 0.3% 
Triton-X (Supplementary Table 2). Following an overnight incubation, 
tissue was washed, then incubated in the appropriate fluorescent sec-
ondary antibodies (goat anti-rabbit, goat anti-mouse at 1:200, Supple-
mentary Table 2) in a PBS solution containing 0.5% Superblock and 
0.3% Triton-X. Tissue was washed again, then counterstained with DAPI 
(1:1000) in PBS for 30 min RT. Sections were then placed in cupric 
sulfate for 15 min at RT to reduce autofluorescence (Schnell et al. 1999) 
and rinsed briefly in dH2O. Finally, sections were mounted, air-dried for 
30 min, coverslipped in DABCO mounting medium (Sigma Aldrich, St. 
Louis, MO, USA), and stored at − 20 ◦C until ready to be imaged. 
2.8. Confocal imaging of oligodendroglial cells 
Fluorescently labeled oligodendroglia were imaged with a Leica TCS 
SPE laser scanning confocal microscope, using UV, 488 and 561 diode 
lasers. To ensure proper blinding, slides were blinded by assigning codes 
prior to imaging. For each section, 12 images were taken through the 
SW, spaced 500 μm apart. Each site was imaged through the z-stack 
using a 40 × 1.3 N.A. oil objective lens at a resolution of 0.135 × 0.135 
× 1.0 μm per voxel. Confocal Z-stack images were deconvolved, and 
converted to 8-bit images using AutoQuant (Media Cybernetics) to 
improve the signal-to-noise ratio, as described (Medalla and Luebke 
2015). 
2.9. Spectral confocal reflectance microscopy imaging 
Spectral Confocal Reflectance (SCoRe) Microscopy as described in 
(Schain et al. 2014; Hill et al. 2018) was used to assess the density of 
myelinated axons at the junction of perilesional grey matter and sub-
lesional white matter (Layer VI). Briefly, 30 μm sections were mounted 
onto gelatin-subbed slides, air-dried for 30 min, then coverslipped using 
prolong gold (ThermoFisher, Waltham, MA, USA). Slides were imaged 
on a Leica TCS SPE laser scanning confocal microscope using a 40 × 1.3 
numerical aperture oil immersion objective by exciting slides with 488, 
561, and 647 laser diodes. Slides were imaged at a resolution of 0.135 ×
0.135 × 1.0 μm per voxel through the z-stack in four regions of Layer VI 
spaced 500 μm apart. 
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2.10. Quantification and analysis of oligodendroglia 
All images were analyzed using ImageJ. To assess densities of 
BCAS1+ (new myelinating cells) and CC1+ (mature oligodendrocytes) 
cells, 8OHdG+ (oxidative DNA damage marker) and Olig2+ (general 
oligodendrocyte marker) cells, and NG2+ oligodendrocyte precursor 
cells, images were opened, channels were split, then merged again to 
create a composite image. To estimate oligodendrocyte cell densities, 
cells were counted through the z-stack using the plugin “Cell Counter” 
(https://imagej.nih.gov/ij/plugins/cell-counter.html), a plugin that al-
lows for manual counting by marking each cell with a marker using 
adapted stereological rules (Fiala and Harris 2001). To analyze oligo-
dendrocytes with and without oxidative DNA damage, blinded double- 
labeled images of 8OHdG+ and Olig2+ cells were separated into oli-
godendrocytes with (Olig2+/8OHdG+) and without oxidative DNA 
damage (Olig2+/8OHdG-). Similarly, slides single-labeled for oligo-
dendrocyte precursor cells positive for NG2 immuno-reactivity were 
analyzed using the cell counter to estimate cell densities. 
To quantify BCAS1+ cells, labeled cells were stratified based on 
morphology and BCAS1+ expression levels. Since BCAS1 is transiently 
expressed during oligodendrocyte maturation, oligodendrocytes were 
separated into distinct maturation stages. Briefly, as described in Fard 
et al. (2017), oligodendrocyte precursor cells (OPCs) first express BCAS1 
only in the soma (BCAS1+/CC1-). As they mature, they express BCAS1+
more strongly in both the soma and in long, radiating processes (30 μm 
or longer; BCAS1++/CC1-). Eventually, CC1, a marker of mature oli-
godendrocytes is expressed in the soma where it colocalizes with 
BCAS1+ cells (BCAS1++/CC1+). Finally, expression of BCAS1+ begins 
to decrease in the processes, but remains in the soma colocalized with 
CC1+, indicating maturation of OPCs into mature oligodendrocytes 
(BCAS1+/CC1+). Next, in the last stage of maturation, BCAS1+
expression ceases, and CC1+ alone is expressed (Fard et al., 2017). Thus, 
for the quantification of oligodendrocytes, with and without BCAS1+
and CC1+ staining, we stratified oligodendrocytes into five distinct 
maturation stages: BCAS1+/CC1-, BCAS1++/CC1-, BCAS1++/CC1+, 
BCAS1+/CC1+, and CC1. 
SCoRe images were analyzed using particle analysis on ImageJ by 
thresholding and assessing the percent area containing reflectance from 
myelinated axons. Additionally, we assessed the directionality and 
orientation of the myelinated fibers using the ImageJ plugin 
“directionality” (https://imagej.net/Directionality), a plugin that as-
signs angular direction to individual fibers and determines the frequency 
of each angular orientation. 
2.11. Enzyme-linked immunosorbent assay myelin basic protein 
To assess myelin damage, we used an Enzyme Linked Immunosor-
bent Assay (ELISA; Ansh Labs, Houston, TX, USA) to measure longitu-
dinal levels of Myelin Basic Protein (MBP) in CSF. Previous literature has 
demonstrated that MBP is found in CSF of patients when a demyelin-
ating lesion is present (Ohta and Ohta 2002). The ELISA was performed 
according to the manufacturer’s protocol. Briefly, CSF samples from 
every time point (pre-operative, 14 days, 28 days, 6 wks, and 14 wks 
after injury) across all animals were thawed at the same time and diluted 
1:2 using assay buffer. Standards were reconstituted according to the 
manufacturer’s protocol and standards and samples were plated in 
duplicate. Samples were gently agitated on an orbital shaker at 800 RPM 
for one hour, then decanted and washed. Samples were then incubated 
in anti-MBP antibody and agitated at 800 RPM for one hour at RT on an 
orbital shaker. Solution was decanted, the plate was washed, and a 
biotinylated conjugate was added, then incubated and agitated for 30 
min at RT at 800 RPM. Solution was decanted again, and the plate was 
washed. Finally, a chromogen detection solution was added and incu-
bated for 20 min in the dark on the orbital shaker and read immediately 
on a plate reader (BioRad, Berkeley, California, USA). 
2.12. RNA isolation and qPCR of myelin related genes 
Fresh-frozen perilesional brain tissue containing white matter 
dissected at euthanasia (14 wks after injury) from all animals was used 
for this study. Tissue samples were removed from − 80 ◦C storage, placed 
on dry ice, then dissected into 100 mg pieces (one for each animal). Each 
sample was mechanically homogenized using an RNAse free scalpel, 
then chemically triturated using the TRIzol method (ThermoFisher, 
Waltham, MA). Briefly, tissue was placed in TRIzol, then passed through 
an 18-gauge needle to further homogenize tissue. An organic extraction 
was then performed using chloroform and ethanol, according to the 
manufacturer’s protocol (ThermoFisher, Waltham, MA). The extracted 
RNA was then air-dried, resuspended in 40 μL of PCR-grade water, then 
checked for A260/280 using a NanoDrop (ThermoFisher, Waltham, 
Fig. 1. Spectral Confocal Reflectance (SCoRe) Microscopy demonstrates increased densities of myelinated axons in the EV group as well as more defined fiber 
orientations. A) Regions of interest for Spectral Confocal Reflectance Microscopy were aligned beneath the lesion, adjacent to the junction of Layer VI. B&C) 
Representative images of myelinated axons in Layer VI of the perilesional grey matter. D) Image analysis of SCoRe images revealed a greater density of myelinated 
axons in the EV group (p = 0.001). E&F) Assessment of the directionality and orientation of the myelinated axons revealed different distributions (Kolmogorov- 
Smirnov test p = 0.04) between Vehicle (E) and EV groups (F). Directionality analyses demonstrated fibers in vehicle treated brains had a relatively uniform 
orientation, confirming the appearance in (B). In contrast, (F) shows axons in the EV group with a bimodal distribution of axon orientation, indicating a more linear, 
grid-like organization (C). Scale bar = 50 μm. 
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MA). 
Following extraction, RNA was converted to cDNA using a High 
Capacity RNA-to-cDNA kit (ThermoFisher, Waltham, MA), according to 
the manufacturer’s protocol, then normalized to 2 μg for each sample. 
Finally, qPCR was performed in triplicate using forward and reverse 
kiqStart primers (Sigma Adlrich, St. Louis, MO) for Myelin Basic Protein 
(MBP), a marker of mature myelinating oligodendrocytes; Myelin Reg-
ulatory Factor (MyRF), a gene for oligodendrocyte differentiation and 
regulation; Breast Carcinoma Amplified Sequence 1 (BCAS1), a gene 
upregulated in new myelinating oligodendrocytes; and GAPDH as a 
housekeeping gene. 
2.13. Data analysis and statistics 
All of the studies were performed with the experimenter blinded to 
treatment groups. To assess any treatment specific group differences, 
Fig. 2. Densities of oligodendrocytes (Olig2) colocalized with 8OHdG, a marker of oxidative DNA damage, showed reduced oxidative damage to oligodendrocytes in 
EV-treated monkeys. Tissue sections stained with Olig2, 8OHdG, and DAPI counterstaining were imaged with confocal microscopy in the sublesional white matter. 
A1, B1, and C1) Oligodendrocytes labeled with Olig2 (general oligodendrocyte marker). A2, B2, and C2) Sections labeled with 8OHdG (oxidative DNA damage). A3, B3, 
and C3) DAPI counterstaining was used to label nuclei. A4, B4, and C4) Merged images of oligodendrocytes stained with 8OHdG, Olig2, and DAPI counterstaining 
represent oligodendrocytes with oxidative DNA damage present. C1 – C4) Representative images of Olig2+ and 8OHdG+ labeling in the contralateral white matter of 
the motor cortex illustrates the typical distribution of Olig2 and 8OHdG labeling in a non-lesioned monkey. D) There were no statistically significant differences in 
the densities of Olig2+ oligodendrocytes without DNA damage in the EV-treated animals (p = 0.13). E) Cell density analysis of Olig2+ oligodendrocytes, co-labeled 
with 8OHdG (DNA damage marker), revealed reduced densities of oligodendrocytes with DNA-damage in the EV-treated animals (p = 0.014). Arrows mark cells co- 
labeled with Olig2+ and 8OHdG+ staining. Scale bar = 50 μm. 
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SCoRe signal and cell density counts were all analyzed using unpaired 
two-sample Student’s t-tests. To further assess the axons (imaged by 
SCoRe), we assessed histogram outputs from the directionality plugin 
and used the Kolmogorov-Smirnov test to assess differences in the dis-
tribution of myelinated axon orientation. To evaluate longitudinal 
measures of Myelin Basic Protein in CSF, a two-way ANOVA was per-
formed to assess any differences between groups or time points. To 
assess relative fold changes of myelin gene expression of the EV group 
relative to the vehicle control group at 14 weeks post-injury, we used the 
ddCT analysis method. Finally, to assess relationships between myelin 
measurements and recovery, we used Pearson’s correlation. Due to the 
availability of using only female subjects in the study, we did not eval-
uate the effect of sex as a variable in any analysis. All tests were analyzed 
using an alpha of p ≤ 0.05 to determine significance. 
2.14. Data availability 
The data that support the findings in this study are available from the 
corresponding author upon request. 
3. Results 
3.1. Density and organization of myelinated axons 
We used Spectral Confocal Reflectance (SCoRe) microscopy to assess 
the density and orientation of myelinated axons in the superficial white 
matter, adjacent to the junction of cortical layer VI within the suble-
sional area (Fig. 1A). SCoRe is a label-free method to image myelin 
reflectance on axons (Fig. 1B&C), thereby visualizing only axons that are 
myelinated (Schain et al. 2014; Hill et al. 2018). Myelin surrounding 
axons that have undergone damage often fragments and becomes 
granular, isotropic, and less organized as the fibers breakdown into 
fragments of myelin debris (Alizadeh et al. 2015). We found that the EV- 
treated group had a significantly greater percent area of SCoRe positive 
(SCoRe+) myelinated axons than the vehicle control group (t(7) =
5.061, p = 0.014, Fig. 1D). Additionally, analyses of the distribution of 
myelinated axon orientation revealed a difference between groups 
(Kolmogorov-Smirnov test, D = 0.211, p = 0.04, Fig. 1E&F). Specif-
ically, the EV group showed a bimodal distribution of myelinated fiber 
orientation (Fig. 1C&F), while the vehicle control group showed a uni-
form distribution, with no clear peak, suggesting a lack of organization 
of the myelinated fibers (Fig. 1B&E). Indeed, SCoRe+ axons in the su-
perficial sublesional white matter exhibited a grid-like appearance in EV 
brains (Fig. 1C), while SCoRe + axons in vehicle brains had randomized 
orientations (Fig. 1B). These data suggest that EV brains have greater 
densities and organization of SCoRe+ axons, which reflects more intact 
myelin with EV treatment after injury (Fig. 1B&C). 
3.2. EV treatment decreases the density of oligodendrocytes with 
oxidative damage 
We then assessed whether EV treatment affected injury-related 
damage of oligodendrocytes by quantifying the densities of oligoden-
drocytes (Olig2) with and without co-labeling of 8OHdG, a marker of 
oxidative DNA damage (Fig. 2A1–C4). When we assessed the density of 
oligodendrocytes without oxidative DNA damage (Olig2+/8OHdG-), we 
found no statistically significant differences between groups (t(7) =
1.723, p = 0.13, Fig. 2D). However, the density of oligodendrocytes with 
oxidative DNA damage (Olig2+/8OHdG+) was lower in the EV-treated 
group (t(7) = 3.275, p = 0.014, Fig. 2E) compared to the vehicle control 
group. These data suggest that EV treatment reduced damage to 
oligodendrocytes. 
3.3. Similar levels of myelin basic protein in CSF longitudinally between 
treatment groups 
The greater densities of myelinated axons quantified using SCoRe 
analysis and the reduction of oligodendrocytes with damaged DNA 
resulting from EV treatment likely reflect less myelin degeneration but 
may also be due to increased oligodendrocyte proliferation and matu-
ration enabling myelin maintenance. Thus, we assessed both myelin 
damage and myelin maintenance using a combination of ELISA, which 
measured Myelin Basic Protein (MBP) in CSF as a marker of damaged 
myelin, and qPCR, to assess myelin-related gene expression as a marker 
of myelin maintenance. Previous literature has demonstrated that high 
levels of MBP are found in the CSF when there is active demyelination 
but low to undetectable levels are found when there is no demyelination 
occurring (Ohta and Ohta 2002). While MBP in CSF is a marker of 
damage, expression of myelin genes at the transcriptomic level, such as 
MBP, MyRF, and BCAS1, is considered a marker of oligodendrocyte 
maturity and myelination, and indicates greater myelin maintenance 
(Michel et al. 2015). 
When we quantified MBP longitudinally in the CSF across the re-
covery period, there were no statistically significant overall differences 
between the treatment groups (F(1,35) = 1.48, p = 0.234, Fig. 3A), time 
points (F(4,35) = 1.911, p = 0.15, Fig. 3A), or interaction between group 
and time points (F(4,35) = 1.734, p = 0.184, Fig. 3A). However, while 
these findings were not significant, there appeared to be an increase in 
MBP levels (at 14 days and at 28 days), as well as increased variability, 
in the vehicle control animals, followed by a gradual decline longitu-
dinally. In contrast, the EV group demonstrated consistently lower levels 
of MBP longitudinally with lower variability, suggesting that there may 
have been less myelin damage in the EV group (Fig. 3A). 
3.4. EV treatment increases myelin gene expression relative to the vehicle 
control 
We further assessed potential changes in myelination by performing 
qRT-PCR on fresh-frozen perilesional tissue to quantify the relative fold 
change in gene expression of factors related to myelin synthesis and 
maintenance in the EV group compared to the vehicle control group at 
14 weeks after injury. As shown in Fig. 3B, we found a 4-fold increase in 
Myelin Regulatory Factor, a gene for myelin regulation and oligoden-
drocyte differentiation, a 1.5-fold increase in Breast Carcinoma Ampli-
fied Sequence 1 (BCAS1+), a marker of new myelinating 
oligodendrocytes, as well as a 1.5-fold increase in the expression of 
Myelin Basic Protein (MBP), a marker of mature oligodendrocytes 
(Fig. 3B). Together, these results suggest that the EV-treatment likely 
enhanced myelination. 
3.5. EV treatment increases the density of BCAS1+ and CC1+
oligodendroglia 
The extent of oligodendrocyte proliferation and maturation can be 
indicative of the degree of myelin turnover (Miron et al. 2011; Zhang 
et al. 2013; Lloyd and Miron 2019). We assessed distinct oligodendro-
cyte populations expressing markers associated with different stages of 
maturation and myelination. We quantified the density of the NG2+
oligodendrocyte precursor cells (OPCs) and found no significant differ-
ences between treatment groups (t(7) = 2.408, p = 0.08, Fig. 4D). We 
then examined potential differences in the densities of differentiated, 
myelinating oligodendrocytes that were positive for CC1 (a marker of 
mature myelinating oligodendrocytes) or BCAS1 (a transient marker of 
new myelinating oligodendrocytes) using stereological counting of in-
dividual cell somata. As shown in Fig. 5, we found a significantly greater 
density of CC1+ cells in EV-treated monkeys compared to vehicle con-
trol monkeys (t(7) = 4.258, p = 0.004, Fig. 5D), indicative of the overall 
greater density of mature myelinating oligodendrocytes. However, the 
overall population of BCAS1 labeled cells did not differ between 
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treatment groups (t(7) = 1.735, p = 0.127, Fig. 5E). 
We then assessed the co-expression of CC1 with BCAS1 to specifically 
label distinct maturation stages of oligodendrocytes. Previous literature 
has suggested that the level of BCAS1 expression represents specific 
stages of myelination (Fard et al. 2017). To assess this, we separated the 
oligodendrocytes into cells with either low BCAS1 expression (BCAS1+) 
or high BCAS1 expression (BCAS1++) defined as cells with BCAS1 
expressed in both the soma as well as multiple processes (~30 μm or 
more, Fig. 6A). We then further stratified cells by assessing co- 
localization with CC1+ (BCAS1+/CC1-, BCAS1++/CC1-, BCAS1++/ 
CC1+, BCAS1+/CC1+). Weakly expressing BCAS1+ cells (BCAS1 
expression restricted to the soma), without immunoreactivity for CC1 
(BCAS1+/CC1-), are thought to be newly transcribing BCAS1+ and are 
cells that are converting from a precursor stage towards a myelinating 
stage. Strongly expressing BCAS1++ cells, with or without co- 
expression of mature oligodendrocyte markers (BCAS1++/CC1- or 
BCAS1++/CC1+) are thought to be more mature than BCAS1+/CC1- 
cells, and are likely to be actively myelinating (Fard et al., 2017). As the 
oligodendrocyte reaches full maturation, BCAS1 immunoreactivity be-
gins to diminish and processes are no longer immunoreactive for 
BCAS1+ labeling, defined by a subset of weakly-expressing BCAS1+
(BCAS1+ only in the soma) mature oligodendrocytes with strong CC1 
expression (BCAS+/CC1+; Fard et al. 2017, Fig. 6C). When oligoden-
drocytes were stratified based on maturation stages, compared to the 
vehicle control group, EV treated brains exhibited a greater density of 
BCAS1++/CC1- (t(7) = 2.673, p = 0.032, Fig. 5G) and BCAS1++/CC1+
(t(7) = 3.242, p = 0.014, Fig. 5H) cells. In contrast, the two groups did 
not significantly differ with regard to the BCAS1+/CC1- oligodendro-
cytes (t(7) = 0.443, p = 0.671, Fig. 5F), nor the BCAS1+/CC1+ cells (t 
(7) = 2.005, p = 0.085, Fig. 5I). Consistent with the differences in myelin 
gene expression, these results suggest that EV treatment may stimulate 
expression of actively-myelinating, BCAS1++ expressing oligodendro-
cytes to promote myelin maintenance. 
3.6. Relationships of oligodendroglia populations and motor recovery 
Finally, we assessed whether the density and distribution of oligo-
dendrocyte populations were correlated with the density of myelinated 
axons, as well as with behavioral measures of recovery (the time to 
recover function) based on data from Moore et al., (2019). We found the 
density of BCAS1++/CC1+ (r = 0.678, p = 0.045, Fig. 7A) and CC1+ (r 
= 0.748, p = 0.021, Fig. 7B) cells were significantly correlated with the 
density of myelinated axons. To further assess whether these cell pop-
ulations were associated with a physiologic outcome, we compared 
these myelin measures with “Days to Return to Pre-Operative Latency” 
as described in Moore et al. (2019). Interestingly, the density of 
myelinated axons strongly correlated with a more rapid rate of func-
tional recovery (r = − 0.866, p = 0.003, Fig. 7C). However, there was no 
significant relationship between the density of BCAS1++/CC1+ cells 
and time to recovery (r = − 0.578, p = 0.103, Fig. 7D). We hypotheiszed 
that there was no significant relationship between denisty and recovery 
time because of potentially opposite correlational trends (i.e. positive vs. 
negative correlations) between groups. However, further correlational 
analyses of group-specific data did not show significant relationships 
between time to recovery and BCAS1++/CC1+ densities. Nevertheless, 
although BCAS1++/CC1+ density and recovery time were not signifi-
cantly correlated, increased densities of CC1+ cells significantly corre-
lated with reduced time to recovery (r = − 0.844, p = 0.004, Fig. 7E). 
These results imply that increased densities of mature oligodendrocytes 
are related to increased densities of myelinated axons as well as reduced 
recovery times. 
4. Discussion 
4.1. Summary of results 
The present study used biochemical, histological, and imaging 
techniques to assess changes in myelin and oligodendrocyte markers in 
the brain tissue and CSF of aged monkeys after cortical injury that were 
treated with MSC-EVs or a vehicle. The overall findings revealed that at 
14 weeks after injury: (1) The density of myelinated axons is greater and 
are more well-organized in the EV treated group; (2) There were 
significantly lower densities of oligodendrocytes with oxidative DNA 
damage (8OHdG+) present in the EV group; (3) While MBP levels in the 
CSF were similar between treatment groups longitudinally, there is 
increased gene expression of myelin-related genes in the EV group, 
Fig. 3. Longitudinal measures of Myelin Basic Protein (MBP) in cerebrospinal fluid (CSF) and Quantitative Real Time – Polymerase Chain Reaction of myelin related 
genes in brain tissue 14 weeks after injury. A) An Enzyme-Linked Immunosorbent Assay (ELISA) was used to assess the levels of Myelin Basic Protein in the CSF 
longitudinally. MBP can be found in the CSF when there is myelin damage present. While EV treatment appeared to reduce a temporal increase in MBP in the CSF in 
the first 4 weeks after the lesion, there were no statistically significant differences between treatment groups (F(1,35) = 1.48, p = 0.234), time points (F(4,35) =
1.911, p = 0.15), or the interaction between group and time points (F(4,35) = 1.734, p = 0.184) when assessed with ANOVA. The space between “Pre-Op” and “14 
days” denotes a gap between the CSF collection timepoints. B) qRT-PCR and the ddCT method were used to quantify fold changes in the EV group relative to the 
vehicle control group in fresh brain tissue collected at euthanasia, 14 weeks after injury. There was a 4-fold increase in the expression of Myelin Regulatory Factor 
(MyRF), a gene necessary for oligodendrocyte differentiation, proliferation, and maintenance, a 1.5-fold increase of Myelin Basic Protein (MBP), a gene expressed by 
mature, myelinating oligodendrocytes, and a similar 1.5-fold increase in Breast Carcinoma Amplified Sequence 1 (BCAS1+), a gene expressed in new myelinating 
oligodendrocytes. 
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relative to the vehicle control group; (4) EV treatment significantly 
increased the density of mature CC1+ cells and new, myelinating 
BCAS1++/CC1-, BCAS1++/CC1+, but not immature BCAS1+/CC1- 
oligodendrocytes. While the BCAS1+/CC1+ cells were not significantly 
different between groups, there was a trend towards increased BCAS1+/ 
CC1+ cells in the EV group; (5) The densities of BCAS1++/CC1+ and 
CC1+ oligodendroglia correlated with increased densities of myelinated 
axons as well as more rapid recovery rates. These results suggest that 
overall, EV treatment reduced myelin damage and enhanced myelin 
maintenance following cortical injury in aged brains. These changes in 
Fig. 4. Oligodendrocyte precursor cell densities are not significantly different between groups. A1, B1, and C1) Confocal images of oligodendrocyte precursor cells 
marked by NG2. A2, B2, and C2) Counterstaining of cell nuclei using DAPI. A3, B3, and C3) Merged images of NG2+ labeling and DAPI counterstaining. C1 – C3) 
Representative images of NG2+ and DAPI labeling in the contralateral white matter of the motor cortex illustrates the typical distribution of NG2+ cells in an un- 
lesioned monkey. D) Analysis of NG2+ cell densities revealed no statistically significant differences in the densities of NG2+ oligodendrocyte precursor between 
groups. Scale bar = 50 μm. 
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myelination likely contributed to EV-mediated recovery of fine motor 
function after cortical injury, as changes in myelination have consis-
tently been shown to be a factor in recovery from brain injury across 
species (Arai and Lo 2009; Wang et al. 2016; Takase et al. 2018). 
4.2. EV treatment limits myelin damage and enhances myelin 
maintenance after cortical injury in the aged brain 
Oligodendrocytes are vulnerable to insults including stroke, Multiple 
Sclerosis, and traumatic brain injury (TBI). Damage to oligodendrocytes 
results in disrupted neurological function (Dewar et al. 2003; Zhang 
et al. 2013), so alimiting oligodendrocyte damage as well as promoting 
oligodendrocyte maturation to stimulate myelin maintenance are crit-
ical factors to restore neurological function after injury or disease 
(Miron et al. 2011; Zhang et al. 2013; Lampron et al. 2015; Shobin et al. 
2017; Lloyd and Miron 2019). In the present study, we examined the 
brain tissue of aged monkeys treated with a novel therapeutic, MSC-EVs, 
which facilitated recovery of function. Specifically, we assessed whether 
MSC-EVs enhanced myelination after injury (Zhang and Chopp 2009; 
Zhang et al. 2013; Moore et al. 2019). 
We first quantified the density of myelinated axons in sublesional 
white matter using ScoRe microscopy and found that there was a greater 
density of myelinated axons in the brains from EV-treated monkeys. 
While interesting, this did not explain whether this was a result of 
limiting demyelination or facilitating myelin maintenance. Thus, we 
performed further studies to assess EV-mediated effects on oligoden-
drocyte damage and maturation. The results showed that, overall, EVs 
acted on both processes to improve myelination. Specifically, we 
showed that there were lower levels of oligodendrocyte oxidative DNA 
damage in the EV treated group compared to the vehicle control group. 
Additionally, qualitative observation of oligodendrocytes showed a 
tendency of Olig2 localization in the nucleus in EV treated animals, 
while typically localizing in the cytoplasm of oligodendrocytes in the 
vehicle control animals. Interestingly, previous literature has shown that 
nuclear Olig2 localization is a characteristic of oligodendrocytes that 
maintain an oligodendrocytic phenotype and are found in maturing or 
fully mature oligodendrocytes (Setoguchi and Kondo 2004; Yokoo et al. 
2004; Cassiani-Ingoni et al. 2006; Zhu et al. 2012). In contrast, Olig2 
that has been exported from the nucleus into the cytoplasm, as seen in 
the vehicle control animals, is generally associated with cells that are 
more likely to switch towards astrocytic phenotypes rather than main-
taining an oligodendrocytic phenotype (Setoguchi and Kondo 2004; 
Yokoo et al. 2004; Cassiani-Ingoni et al. 2006; Zhu et al. 2012). Hence, 
while Olig2+ cells in the EV group showed Olig2+ localization in the 
nucleus, likely indicating a stable oligodendrocytic phenotype, Olig2 
immunoreactivity in the cytoplasm of the vehicle control animals sug-
gests a shift away from the oligodendrocytic phenotypes towards an 
astrocytic phenotype. This further suggests that oligodendrocyte func-
tion and myelination was maintained and enhanced in the EV-treated 
group. Future studies are needed to further explore the potential 
phenotypic shift in oligodendrocyte populations between groups. 
Next, at 14 weeks post-injury, we found that the EV-treated group 
had increased gene expressions of MyRF (regulation and differentiation 
of oligodendrocytes), MBP (mature oligodendrocytes), and BCAS1 (new 
myelinating oligodendrocytes), which are myelin-production related 
genes that are upregulated during myelin maintenance (Miron et al. 
2011; Lloyd and Miron 2019). To further analyze oligodendrocyte 
maintenance, we assessed the densities of immature, maturing, and 
mature oligodendrocyte populations. Our data demonstrated that EV- 
treatment was associated with greater densities of oligodendroglia 
that were are associated with more mature stages of myelinating oli-
godendrocytes (BCAS1++/CC1+ (myelinating & mature), BCAS1++/ 
CC1- (myelinating but not fully mature), and CC1+ (mature and stable) 
cells (Fard et al., 2017)). However, we found no significant differences 
Fig. 5. Greater densities of myelinating oligodendrocytes in the EV-treated group. A1, B1, and C1) Representative images of oligodendrocytes stained with BCAS1, a 
marker of new myelinating oligodendrocytes. A2, B2, and C2) Oligodendrocytes labeled with CC1, a marker of mature, myelinating oligodendrocytes. A3, B3, and C3) 
DAPI counterstaining was used to label cell nuclei. C1 – C4) Representative images of BCAS1+, CC1+, and DAPI labeling in the contralateral white matter of the 
motor cortex represents the typical distribution of BCAS1+ and CC1+ cells. D) There were significantly more CC1+ cell densities (p = 0.004) in the EV animals. E) 
The combined densities of all BCAS1+ cells were not different between treatment groups (p = 0.12). F–I) The BCAS1+ cells were further stratified into the various 
stages of maturation (BCAS1+/CC1-, BCAS1++/CC1-, BCAS1++/CC1+, BCAS1+/CC1+). Within these subpopulations, we found F) no statistically significant 
differences between groups in the BCAS1+/CC1- cells (p = 0.67). G) We found greater densities of BCAS1++/CC1- cells (p = 0.03) and H) BCAS1++/CC1+ cells (p 
= 0.01) in the EV group. I) However, the densities of BCAS1+/CC1+ cells were not different between groups (p = 0.12). Scale bar = 50 μm. 
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Fig. 6. BCAS1 defines a population of new myelinating oligodendrocytes. Confocal images showing cells with BCAS1 and CC1 labeling were stratified into five 
classes to identify oligodendrocytes at various stages of maturation: BCAS1+/CC1-, BCAS1++/CC1-, BCAS1++/CC1+, BCAS1+/CC1+, and BCAS1-/CC1+. A) High 
expressing BCAS1 (BCAS1++) cells were identified as cells that were immuno-reactive to BCAS1 staining both in the soma and radiating processes. B&E) CC1+
expression labeled mature, myelinating oligodendrocytes. C) A merged image of a high expressing BCAS1+ cell, with CC1+ staining. D) Low expressing BCAS1+ cells 
were defined by low BCAS1 immunoreactivity in the cell processes, and strong immunoreactivity constrained to the soma. F) A merged image of low expressing 
BCAS1+ cells with and without CC1+ co-labeling. Arrows mark cells co-labeled with BCAS1+ and CC1+ staining. Scale bar = 50 μm. 
Fig. 7. Densities of myelinating oligodendrocytes correlate with the density of myelinated axons and motor recovery. A) The density of BCAS1++/CC1+ cells 
correlated with increased densities of myelinated axons (p = 0.045). B) The density of CC1+ oligodendrocytes correlated with increased densities of myelinated 
axons (p = 0.021). C) The density of myelinated axons correlated with reduced time to recovery (p = 0.003). D) The density of BCAS1++/CC1+ cells did not have a 
statistically significant relationship with time to recovery (p = 0.103). E) However, the density of CC1+ cells significantly correlated with reduced time to recovery 
(p = 0.004). 
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in the densities of NG2+ OPCs nor the immature stages of oligoden-
drocyte maturation (BCAS1+/CC1-) between groups. 
Finally, we assessed the relationships of oligodendrocyte densities 
with the densities of myelinated axons (SCoRe) and measures of re-
covery of fine motor function of the hand (Moore et al. 2019) with and 
without EV treatment. We found that mature oligodendrocyte pop-
ulations were correlated with greater densities of myelinated axons and 
reduced time to recover to baseline fine motor functions. Overall, our 
results suggest that EVs reduced damage to oligodendrocytes, promoted 
oligodendrocyte maturation to enhance myelin maintenance in aged 
brains, and likely underlies the enhanced motor recovery shown in 
Moore et al. (2019). Thus, while future experiments are needed to spe-
cifically examine the effect of EVs on oligodendrocyte maturation, our 
findings suggest that EV treatment specifically facilitated myelination 
and recovery. 
4.3. Potential mechanisms and additional EV targets 
In the present study, we focused on assessing changes in oligoden-
drocytes and myelin in vivo. Our data are consistent with in vitro studies 
showing that MSC-EVs promote neuronal growth and increase myeli-
nation in organotypic slice cultures, likely through the miR-17-92 
cluster (Xin et al. 2017; Zhang et al. 2019), while also promoting sur-
vival, proliferation and maturation of oligodendrocytes in primary cul-
tures (Miron et al. 2011; Kurachi et al. 2016; Osorio-Querejeta et al. 
2018; Lloyd and Miron 2019). Further in vivo studies in rodent models of 
injury have shown that MSC-EVs stimulate myelination and promote 
oligodendrocyte survival (Ma et al. 2017). However, whether EVs act 
directly or indirectly on oligodendrocytes, neurons, or other glial types 
in vivo remains unknown. EVs likely act on many cell types to enhance 
recovery, especially since EVs contain a wide variety of miRNA, RNA, 
and protein (Anderson et al. 2016; Phinney and Pittenger 2017; Fergu-
son et al. 2018; Go et al. 2019). Because there is a plethora of molecular 
contents in EVs, EVs have the potential to modulate multiple cell types in 
the CNS, such as neurons, astrocytes, endothelial cells, microglia, and 
peripheral immune cells to reduce pathology and enhance recovery (Xin 
et al. 2012, 2013; Go et al. 2019; Zhang et al. 2019; Medalla et al. 2020). 
While it would be beneficial to determine the distribution of EVs within 
cells in our monkey model of cortical injury. 
We did not perform any biodistribution analyses in the current study 
due to the necessity of sacrificing animals acutely after drug injection, 
which is a limitation of the study. However, previous in vitro and in vivo 
studies have shown that EVs are preferentially engulfed by endothelial 
cells, neurons, and glia localizing to perilesional areas after injury 
(Zhang et al. 2019). Thus, while it is impossible to know whether our 
EVs reached the site of injury to act locally, it is plausible. Additionally, 
while EVs can act directly on CNS cells, they can also act indirectly by 
modulating cells to perform different biological functions and influence 
neighboring cells (Zhang et al. 2019). For instance, it is possible that 
changes in microglial reactivity could influence surrounding cells (Go 
et al. 2019). Specifically, microglial shifts from damaging, reactive 
phenotypes towards surveilling phenotypes could increase the release of 
growth factors and anti-inflammatory cytokines to promote regenera-
tion and neurorestoration after injury (Patel et al. 2013; Go et al. 2019). 
Additionally, it is now known that myelin dynamics are often influenced 
by the activity of neurons (de Faria et al. 2019). Indeed, our previous 
work has specifically shown that EV treatment reduced microgliosis (Go 
et al. 2019), and neuronal pathology (Medalla et al. 2020). Therefore, 
while we show here that EVs clearly modulate myelination after cortical 
injury, it is unclear whether the changes in oligodendrocytes and myelin 
maintenance was a direct or indirect effect of EV therapy. It is likely that 
the effects of EVs on each of these cell populations and the interactions 
between the cells targeted have a combined effect on motor recovery in 
our monkey model of cortical injury, which may not be possible to 
disentangle. For example, while we showed that oxidative DNA damage 
was reduced in the oligodendrocytes of EV-treated monkeys, additional 
modes of damage to oligodendrocytes, such as degrading enzymes or 
pro-inflammatory cytokines, may have also contributed to oligoden-
drocyte damage (Sloane et al. 2003; Chavez et al. 2009; Tse and Herrup 
2017). Thus, while this report has focused on changes in oligodendro-
cytes, EV treatment likely modulated many cell types, both directly and 
indirectly, to improve recovery. Finally, while previous proteomic and 
transcriptomic studies have characterized the contents of human, 
porcine, and rodent MSC-EVs, (Anderson et al. 2016; Eirin et al. 2016; 
Ferguson et al. 2018; van Balkom et al., 2019), the constituents of the 
monkey MSC-EVs used here have not been characterized. Future work is 
geared towards large scale proteomic and transcriptomic analyses to 
identify the active components in these monkey EVs, as well as using in 
vitro models to tease apart the precise molecular pathways and cellular 
targets modulated by EV-treatment. 
4.4. Implications for the aged brain and white matter pathologies 
The efficacy of EVs in enhancing oligodendrocyte and myelin 
maintenance after cortical injury shown here is consistent with the use 
of EVs as treatment for other brain pathologies where white matter is 
affected, such as Multiple Sclerosis, Spinal Cord Injury, Chronic Trau-
matic Encephalopathy, and aging (Xin et al. 2012; Rani et al. 2015; 
Williams et al. 2019). Most relevant to the current study is the growing 
evidence of the efficacy of MSC-EVs as a possible intervention in aging 
(Panagiotou et al. 2018). Normal brain aging is characterized by chronic 
myelin pathology and oligodendrocyte dysfunction, which are strongly 
correlated with age-related cognitive decline (Bowley et al. 2010; Schain 
et al. 2014; de Lange et al. 2016). Further, there is evidence showing that 
this age-related white matter damage is linked to chronic inflammation 
(Duce et al. 2006; Shobin et al. 2017). The accumulation of myelin 
damage, inflammation, and oxidative stress in the aged brain underlies 
its increased susceptibility to ischemic brain injury (Crack and Taylor 
2005; Gemma et al. 2007; Shobin et al. 2017), but also represents spe-
cific candidate targets for interventions (Cornejo and von Bernhardi, 
2016; Robillard et al., 2016; Safaiyan et al., 2016; Xie et al., 2013). 
Previous work in monkeys from our laboratory has shown age- 
related increases in myelin damage (Peters 2002; Bowley et al. 2010) 
and microglial activation (Shobin et al. 2017) associated with cognitive 
decline in aged monkeys. This is of particular interest to the present 
study, as the brain tissue and CSF came from monkeys within the age 
range in which we begin to see myelin atrophy, white matter degener-
ation, and cognitive decline (Shobin et al. 2017). The comprehensive 
findings in this study show that EVs reduce myelin damage and enhance 
myelin maintenance following cortical injury in aged brains. Overall, 
these findings provide rationale for testing MSC-EVs for white matter 
pathologies associated not only acquired neurological injuries or 
degenerative diseases, but also with normal aging. 
4.5. Future directions and limitations 
One limitation of the study is that the temporal sequence of MSC-EV 
action on oligodendrocytes cannot be addressed given the current cross- 
sectional model with brain tissue harvested at 14 weeks after injury. 
Therefore, future studies are needed to examine brain tissue at earlier 
timepoints to assess myelination across the recovery period. While it 
would be ideal to assess tissue across the entirety of the recovery period, 
including at 24 h after injury, the feasibility of these experiments is 
challenging due to the high cost of monkeys and resources necessary to 
complete these studies. Additionally, our sample size was small and was 
limited only to female subjects. An increased sample size including both 
sexes will be needed in the future to not only confirm some of the trends 
observed in this study, but to also address potential sex-related effects. 
An increase in sample size will also allow within-group correlation an-
alyses that may reveal treatment-specific relationships of myelination 
and recovery. An additional caveat with this study is the use of a single 
donor of MSC-EVs. While the therapeutic effects of EVs from multiple 
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donors will be important to study in the future, the use of a single donor 
in this study limited the variability that could arise from using EVs from 
various donors. Furthermore, future work using novel monkey and 
human in vitro culture and organoid systems will be important to char-
acterize the precise molecular pathways and the mechanisms of action of 
MSC-EVs on oligodendrocytes and other cell types. Thus, while we show 
the therapeutic benefits of EVs on myelination and functional recovery 
in our aged monkey model of cortical injury in vivo, additional studies 
are needed to further characterize the mechanisms that underlie the full 
therapeutic potential of MSC-EVs. 
5. Conclusions 
This study provides novel evidence in aged rhesus monkeys sup-
porting the hypothesis that MSC-EVs act on oligodendrocytes to facili-
tate recovery of function. Specifically, we show that EV treatment likely 
did this in part by limiting damage to oligodendrocyte DNA and by 
enhancing myelin maintenance through upregulating myelin-related 
gene expression and increasing the population of actively-myelinating 
oligodendrocytes. While these results emphasize the importance of 
oligodendroglia and myelin, it is likely that MSC-EVs also modified 
other cells to enhance recovery of function. Thus, while our results 
explain some of the cellular changes that enhanced recovery, they likely 
only partially explain the cellular and molecular changes that occurred 
with EV-treatment to enhance overall recovery after cortical injury. 
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